

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	6
-------	---	----	---

Complete if Known

Application Number	10/059,627
Filing Date	January 29, 2002
First Named Inventor	Yawei Ni, et al.
Group Art Unit	2354 1654
Examiner Name	unknown - <i>Melter</i>
Attorney Docket Number	CARR-0084 (103216.00252)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

NOV 25 2002
TECH CENTER 1600/2900



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	10/059,627
Filing Date	January 29, 2002
First Named Inventor	Yawei Ni, et al.
Group Art Unit	1751
Examiner Name	unknown
Attorney Docket Number	CARR-0084 (103216.00252)

RECEIVED
NOV 21 2002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	B1	AARONSON, STUART A., ET AL., "Keratinocyte Growth Factor. A Fibroblast Growth Factor Family Member with Unusual Target Cell Specificity", Annals of the New York Academy of Sciences, 1991, Vol. 638, Pages 62-77	
	B2	BAJAJ-ELLIOTT, MONA, ET AL., "Keratinocyte Growth Factor in Inflammatory Bowel Disease. Increased mRNA Transcripts in Ulcerative Colitis Compared with Crohn's Disease in Biopsies and Isolated Mucosal Myofibroblasts", American Journal of Pathology, November 5, 1997, Vol. 151 (No. 5), Pages 1469-1476	
	B3	BASKIN, LAURENCE S., ET AL., "Growth Factors in Bladder Wound Healing", Journal of Urology, June 1997, Vol. 157, Pages 2388-2395	
	B4	BECHTEL, MICHAEL J., ET AL., "Upregulation of Cell-Surface-Associated Plasminogen Activation in Cultured Keratinocytes by Interleukin-1 β and Tumor Necrosis Factor- α ", Experimental Cell Research, 1996, Vol. 223, Pages 395-404	
	B5	BEER, HANS-DIETMAR, ET AL., "Mouse Fibroblast Growth Factor 10: cDNA Cloning, Protein Characterization and Regulation of mRNA Expression", Oncogene, 1997, Vol. 15, Pages 2211-2218	
	B6	BELLOSTA, P, ET AL., "Cleavage of K-FGF Produces a Truncated Molecule with Increased Biological Activity and Receptor Binding Affinity", Journal of Cell Biology, 1993, Vol. 121, Pages 705-713	
	B7	BUGGE, THOMAS H., ET AL., "Loss of Fibrinogen Rescues Mice from the Pleiotropic Effects of Plasminogen Deficiency", Cell, 1996, Vol. 87, Pages 709-719	
	B8	CARMEIET, PETER, ET AL., "Genetic Analysis of Blood Vessel Formation Role of Endothelial Versus Smooth Muscle Cells", Trends in Cardiovascular Medicine, 1997, Vol. 7, Pages 271-281	
	B9	CARMEIET, PETER, ET AL., "Inhibitory Role of Plasminogen Activator Inhibitor-1 in Arterial Wound Healing and Neointima Formation - A Gene Targeting and Gene Transfer Study in Mice", Circulation, 1997, Vol. 96, Pages 3180-3191	
	B10	CARMEIET, PETER, ET AL., "Development and Disease in Proteinase-Deficient Mice: Role of the Plasminogen, Matrix Metalloproteinase and Coagulation System", Thrombosis Research, 1998, Vol. 91, Pages 255-285	
	B11	CHEDID, MARCIO, ET AL., "Glucocorticoids Inhibit Keratinocyte Growth Factor Production in Primary Dermal Fibroblasts", Endocrinology, 1996, Vol. 137, Pages 2232-2237	
	B12	COLLEN, DESIRE, ET AL., "Fibrinolysis and the Control of Hemostasis", The Molecular Basis of Blood Diseases, Ed. G. S. Stamatoyannopoulos, A. W. Nienhuis, P. W. Majerus, and H. Varmus. Philadelphia: W. B. Saunders Co., 1994, Pages 725-752	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	10/059,627
Filing Date	January 29, 2002
First Named Inventor	Yawei Ni, et al.
Group Art Unit	1751
Examiner Name	unknown
Attorney Docket Number	CARR-0084 (103216.00252)

RECEIVED
NOV 27 2002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	B13	COLLEN, DESIRE, "The Plasminogen (Fibrinolytic) System", Thrombosis and Haemostasis, 1999, Vol. 82, Pages 259-270	
	B14	FARRELL, CATHERINE L., ET AL., "Keratinocyte Growth Factor Protects Mice from Chemotherapy and Radiation-induced Gastrointestinal Injury and Mortality", Cancer Research, 1998, Vol. 58, Pages 933-939	
	B15	FEHRENBACH, H., ET AL., "Keratinocyte Growth Factor-induced HyperPlasia of Rat Alveolar Type II Cells <i>in Vivo</i> is Resolved by Differentiation into Type I Cells and by Apoptosis", European Respiratory Journal, 1999, Vol. 14, Pages 534-544	
	B16	FINCH, PAUL W., ET AL., "Human KGF Is FGF-Related with Properties of a Paracrine Effector of Epithelial Cell Growth", Science, 1989, Vol. 245, Pages 752-755	
	B17	FOLKMAN, JUDAH, "Seminars in Medicine of the Beth Israel Hospital, Boston, Clinical Applications of Research of Angiogenesis", New England Journal of Medicine, 1995, Vol. 333, Pages 1757-1763	
	B18	GILLIS, PAUL, ET AL., "Keratinocyte Growth Factor Induces Angiogenesis and Protects Endothelial Barrier Function", Journal of Cell Science, 1999, Vol. 112, Pages 2049-2057	
	B19	HELISCH, ARMIN, ET AL., "Therapeutic Angiogenesis in Ischemic Heart Disease", Thrombosis and Haemostasis, 1999, Vol. 82, Pages 772-780	
	B20	HEYMANS, S., ET AL., "Inhibition of Plasminogen Activators or Matrix Metalloproteinases Prevents Cardiac Rupture but Impairs Therapeutic Angiogenesis and Causes Cardiac Failure", Nature Medicine, 1999, Vol. 5, Pages 1135-1142	
	B21	HIRAOKA, NOBUAKI, ET AL., "Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins", Cell, 1998, Vol. 95, Pages 365-377	
	B22	HOFFMAN, RICHARD, ET AL., "Wound Fluid from Venous Leg Ulcers Degrades Plasminogen and Reduces Plasmin Generation by Keratinocytes", Journal of Investigative Dermatology, 1998, Vol. 111, Pages 1140-1144	
	B23	IGARASHI, MAKOTO, ET AL., "Characterization of Recombinant Human Fibroblast Growth Factor (FGF)-10 Reveals Functional Similarities with Keratinocyte Growth Factor (FGF-7)", The Journal of Biological Chemistry, 1998, Vol. 273, Pages 13230-13235	
	B24	JIMENEZ, PABLO A., ET AL., "Keratinocyte Growth Factor-2 Accelerates Wound Healing in Incisional Wounds", Journal of Surgical Research, 1999, Vol. 81, Pages 238-242	

Examiner
Signature

Date
Considered

4/22/04

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet 4 of 6

Compleat if Known

Application Number	10/059,627
Filing Date	January 29, 2002
First Named Inventor	Yawei Ni, et al.
Group Art Unit	1751
Examiner Name	unknown
Attorney Docket Number	CARR-0084 (103216.00252)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B25	JOHNSON, DANIEL E., ET AL., "Structural and Functional Diversity in the FGF Receptor Multigene Family", Advances in Cancer Research, 1993, Vol. 60, Pages 1-41	
	B26	KAO, WINSTON W., ET AL., "Healing of Corneal Epithelial Defects in Plasminogen-and-Fibrinogen-Deficient Mice", Investigative Ophthalmology & Visual Science, 1998, Vol. 39, Pages 502-508	
	B27	KOMOROWIEZ, ERZSEBET, ET AL., "Fibrinolysis with Des-Kringel Derivatives of Plasmin and its Modulation by Plasma Protease Inhibitors", Biochemistry, 1998, Vol. 37, Pages 9112-9118	
	B28	LU, WEIQIN, ET AL., "Fibroblast Growth Factor-10. A Second Candidate Stromal to Epithelial Cell Andromedin in Prostate", The Journal of Biological Chemistry, 1999, Vol. 274, Pages 12827-12834	
	B29	LUND, LEIF R., ET AL., "Functional Overlap between Two Classes of Matrix-degrading Proteases in Wound Healing", The European Molecular Biology Organization Journal, 1999, Vol. 18, Pages 4645-4656	
	B30	MARCHESE, CINZIA, ET AL., "Modulation of Keratinocyte Growth Factor and its Receptor in Reepithelializing Human Skin", Journal of Experimental Medicine, 1995, Vol. 182, Pages 1369-1376	
	B31	MCKEEHAN, WALLACE L., ET AL., "The Heparan Sulfate-Fibroblast Growth Factor Family: Diversity of Structure and Function", Progress in Nucleic Acid Research & Molecular Biology, 1998, Vol. 59, Pages 135-176	
	B32	MORIKOA, SHINJI, ET AL., "Migrating Keratinocytes Express Urokinase-Type Plasminogen Activator", Journal of Investigative Dermatology, 1987, Vol. 88, Pages 418-423	
	B33	ODEKON, LALE E., ET AL., "Requirement for Receptor-Bound Urokinase in Plasmin-Dependent Cellular Conversion of Latent TGF-β to TGF-β", Journal of Cellular Physiology, 1994, Vol. 158, Pages 398-407	
	B34	OSSLUND, TIMOTHY D., ET AL., "Correlation Between the 1.6 Angstrom Crystal Structure and Mutational Analysis of Keratinocyte Growth Factor", Protein Science, 1998, Vol. 7, Pages 1681-1690	
	B35	ROMER, JOHN, ET AL., "The Receptor for Urokinase-type Plasminogen Activator is Expressed by Keratinocytes at the Leading Edge During Re-Epithelialization of Mouse Skin Wounds", Journal of Investigative Dermatology, 1994, Vol. 102, Pages 519-522	
	B36	ROMER, JOHN, ET AL., "Impaired Wound Healing in Mice with a Disrupted Plasminogen Gene", Nature Medicine, 1996, Vol. 2, Pages 287-292	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 6

Complete if Known

Application Number	10/059,627
Filing Date	January 29, 2002
First Named Inventor	Yawei Ni, et al.
Group Art Unit	1751
Examiner Name	unknown
Attorney Docket Number	CARR-0084 (103216.00252)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JMM	B37	RON, DINA, ET AL., "Expression of Biologically Active Recombinant Keratinocyte Growth Factor. Structure/Function Analysis of Amino-Terminal Truncation Mutants", Journal of Biological Chemistry, 1993, Vol. 268, Pages 2984-2988	
	B38	RUBIN, JEFFREY S., ET AL., "Purification and Characterization of a Newly Identified Growth Factor Specific for Epithelial Cells", Proceedings of the National Academy of Sciences of the United States of America, 1989, Vol. 86, Pages 802-806	
	B39	SALVA, USHMA, ET AL., "Barrier Function of Airway Epithelium: Effects of Radiation and Protection by Keratinocyte Growth Factor", Radiation Research, 1998, Vol. 150, Pages 195-203	
	B40	SCHLESSINGER, JOSEPH, ET AL., "Regulation of Growth Factor Activation by Proteoglycans: What is the Role of the Low Affinity Receptors?", Cell, November 3, 1995, Vol. 83, Pages 357-360	
	B41	STAIANO-COICO, LISA, ET AL., "Human Keratinocyte Growth Factor Effects in a Porcine Model of Epidermal Wound Healing", Journal of Experimental Medicine, 1993, Vol. 178, Pages 865-878	
	B42	TAGASHIRA, SHUZO, ET AL., "Cloning of Mouse FGF10 and Up-Regulation of Its Gene Expression During Wound Healing", Gene, 1997, Vol. 197, Pages 399-404	
	B43	TSUBOI, RYOJI, ET AL., "Keratinocyte Growth Factor (FGF-7) Stimulates Migration and Plasminogen Activator Activity of Normal Human Keratinocytes", Journal of Investigative Dermatology, 1993, Vol. 101, Pages 49-53	
	B44	VAN SETTEN, GYSBERT-BOTH, ET AL., "Plasmin and Plasminogen Activator Activities in Tear Fluid During Corneal Wound Healing after Anterior Keratectomy", Current Eye Research, 1989, Vol. 8, Pages 1293-1298	
	B45	WEISSMAN, BERNARD E., ET AL., "BALB and Kirsten Murine Sarcoma Viruses alter Growth and Differentiation of EGF-Dependent BALB/c Mouse Epidermal Keratinocyte Lines", Cell, 1983, Vol. 32, Pages 599-606	
	B46	WERNER, SABINE, ET AL., "Large Induction of Keratinocyte Growth Factor Expression in the Dermis during Wound Healing", Proceedings of the National Academy of Sciences of the United States of America, 1992, Vol. 89, Pages 6896-6900	
V	B47	WERNER, SABINE, ET AL., "The Function of KGF in Morphogenesis of Epithelium and Reepithelialization of Wounds", Science, 1994, Vol. 266, Pages 819-822	
	B48	WERNER, SABINE, "Keratinocyte Growth Factor: A Unique Player in Epithelial Repair Processes", Cytokine & Growth Factor Reviews, 1998, Vol. 9, Pages 153-165	

Examiner
SignatureDate
Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
NOV 25 2002
TECH CENTER 1600/2900

RECEIVED



Institute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/059,627
		Filing Date	January 29, 2002
		First Named Inventor	Yawei Ni, et al.
		Group Art Unit	1751
		Examiner Name	unknown
Sheet 6 of 6	Attorney Docket Number	CARR-0084 (103216.00252)	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Mm v	B49	WU, LIANCUN, ET AL., "Keratinocyte Growth Factor Induces Granulation Tissue in Ischemic Dermal Wounds. Importance of Epithelial-Mesenchymal Cell Interactions", Archives of Surgery, 1996, Vol. 131, Pages 660-666	
	B50	YAMASAKI, MASAHIRO, ET AL., "Structure and Expression of the Rat mRNA Encoding a Novel Member of the Fibroblast Growth Factor Family", Journal of Biological Chemistry, 1996, Vol. 271, Pages 15918-15921	
	B51	ZEEH, JORG M., ET AL., Kertinocyte Growth Factor Ameliorates Mucosal Injury in an Experimental Model of Colitis in Rats, Gastroenterology, 1996, Vol. 110, Pages 1077-1083	
	B52	ZHENG, JIE, ET AL., "Keratinocyte Growth Factor Enhances Urokinase-Type Plasminogen Activator Activity in HPV16 DNA-Immortalized Human Uterine Exocervical Epithelial Cells", 1996, European Journal of Cell Biology, 1996, Vol. 69, Pages 128-134	

Examiner Signature		Date Considered	4/22/04
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
do not respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/059,627
--------------------	------------

Filing Date	January 29, 2002
-------------	------------------

First Named Inventor	Yawei Ni, et al.
----------------------	------------------

Group Art Unit

Examiner Name

Attorney Docket Number

10/059,627

January 29, 2002

Yawei Ni, et al.

1354 16

~~unknown~~

CARR-0084 (103216.00252)

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	1
-------	---	----	---

Application Number	10/059,627
Filing Date	January 29, 2002
First Named Inventor	Yawei Ni
Art Unit	1654
Examiner Name	M. Meller
Attorney Docket Number	103216.00252

[illegible]

4/22/04

² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

3511960v1